1. Home
  2. LABT vs DKI Comparison

LABT vs DKI Comparison

Compare LABT & DKI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakewood-Amedex Biotherapeutics Inc. Common Stock

LABT

Lakewood-Amedex Biotherapeutics Inc. Common Stock

N/A

Current Price

$0.20

Market Cap

670.6K

Sector

Health Care

ML Signal

N/A

DKI

DarkIris Inc. Class A Ordinary Shares

N/A

Current Price

$1.56

Market Cap

718.2K

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
LABT
DKI
Founded
2006
2018
Country
United States
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
670.6K
718.2K
IPO Year
2026
2025

Fundamental Metrics

Financial Performance
Metric
LABT
DKI
Price
$0.20
$1.56
Analyst Decision
Analyst Count
0
0
Target Price
★ $7.50
N/A
AVG Volume (30 Days)
607.7K
★ 14.5M
Earning Date
11-18-2026
08-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.22
$0.04
52 Week High
$6.85
$9.13

Technical Indicators

Market Signals
Indicator
LABT
DKI
Relative Strength Index (RSI) 16.87 50.52
Support Level N/A $0.29
Resistance Level $2.13 $2.43
Average True Range (ATR) 0.06 0.21
MACD 0.01 0.24
Stochastic Oscillator 1.52 63.21

Price Performance

Historical Comparison
LABT
DKI

About LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock

Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.

About DKI DarkIris Inc. Class A Ordinary Shares

Darkiris Inc is a comprehensive technology enterprise engaged in the development, publishing and operating of mobile digital games via various third-party digital storefronts. Its activities encompass including game design, programming and graphics, as well as distribution and operation of mobile games on various platforms. Its core product offerings are Games Development; develop, market and distribute its self-developed mobile games; and Games Publishing and Operation. It publish and operate its self-developed mobile games and mobile games it license from other game developers.

Share on Social Networks: